Terminated PHASE1 INTERVENTIONAL 1-arm NCT00713765

Pharmacokinetic Interaction Between AZD3480 and Donepezil

A Double-blind, Randomised, Cross-over, Placebo-controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6

Sponsor: AstraZeneca

Conditions Alzheimer's Disease

Interventions AZD3480 Donepezil

Updated 5 times since 2017 Last updated: Aug 12, 2014 Started: Dec 31, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Ended prematurely - The trial never commenced.

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Alzheimer's Disease trials with similar outcome

Browse all Alzheimer's Disease trials

Listed as NCT00713765, this PHASE1 trial focuses on Alzheimer's Disease and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manchester, United Kingdom